Cardiovascular risk assessment and lipid modification

with their healthcare professional. Source guidance Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238 (2023), recommendation 1.7.1 Definitions of terms used in this quality statement Adults with cardiovascular disease Including coronary heart disease, ischaemic stroke or TIA (excluding a history of haemorrhagic stroke) or peripheral arterial disease. [Adapted from Quality and Outcomes Framework indicator CHOL004, NICE's indicator on cardiovascular disease prevention: secondary prevention with lipid lowering therapies and expert opinion] Update information July 2025: This quality standard was updated and statements prioritised in 2015 were replaced. The topic was identified for update following the annual review of quality standards. The review identified updated guidance on cardiovascular disease: risk assessment and reduction, including lipid modification. Statements are marked as: • [new 2025] if the statement covers a new area for quality improvement • [2015, updated 2025] if the statement covers an area for quality improvement included in the 2015 quality standard and has been updated. The previous version of the quality standard for cardiovascular risk assessment and lipid modification is available as a pdf. Minor changes since publication September 2025: We update the source guidance for statement 3 to align with updated recommendations in NICE's guideline on
